scholarly journals Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor–Positive Early Breast Cancer: Lights and Shadows

2019 ◽  
Vol 37 (11) ◽  
pp. 862-866 ◽  
Author(s):  
Meredith M. Regan ◽  
Gini F. Fleming ◽  
Barbara Walley ◽  
Prudence A. Francis ◽  
Olivia Pagani
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Systemic Treatment ◽  
Premenopausal Women ◽  
Adjuvant Systemic Treatment ◽  
Hormone Receptor Positive

scholarly journals Management of early breast cancer during the COVID-19 pandemic in Brazil

2020 ◽  
Author(s):  
Francisco Pimentel Cavalcante ◽  
Guilherme Garcia Novita ◽  
Eduardo Camargo Millen ◽  
Felipe Pereira Zerwes ◽  
Vilmar Marques de Oliveira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Reconstruction ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Premenopausal Women ◽  
Management Approach ◽  
Autologous Reconstruction ◽  
Hormone Receptor Positive ◽  
Neoadjuvant Systemic Therapy ◽  
The Impact

Abstract Purpose: The COVID-19 pandemic has impacted early breast cancer (EBC) treatment worldwide. This study analyzed how Brazilian breast specialists are managing EBC. Methods: An electronic survey was conducted with members of the Brazilian Society of Breast Specialists between April 30 and May 11, 2020. Bivariate analysis was used to describe changes in how specialists managed EBC at the beginning and during the pandemic, according to molecular subtype and oncoplastic surgery. Results: The response rate was 34.4% (503/1,462 specialists). At the beginning of the pandemic, 43% changed their management approach. As the outbreak progressed, this proportion increased to 69.8% (p<0.001). For hormone receptor-positive tumors with the best prognosis (Ki67<20%), 47.9% and 17.7% of specialists would recommend neoadjuvant endocrine therapy for postmenopausal and premenopausal women, respectively. For tumors with poorer prognosis (Ki67>30%), 34% and 10.9% would recommend it for postmenopausal and premenopausal women, respectively. Menopausal status significantly affected whether the specialists changed their approach (p<0.00001). For tumors ≥1.0 cm, 42.9% of respondents would recommend neoadjuvant systemic therapy for triple-negative tumors and 39.6% for HER2+ tumors. Overall, 63.4% would recommend immediate total breast reconstruction, while only 3.4% would recommend autologous reconstruction. In breast-conserving surgery, 75% would recommend partial breast reconstruction; however, 54.1% would contraindicate mammoplasty. Furthermore, 84.9% of respondents would not recommend prophylactic mastectomy in cases of BRCA mutation.Conclusions: Important changes occurred in EBC treatment, particularly for hormone receptor-positive tumors, as the outbreak progressed in each region. Systematic monitoring could assure appropriate breast cancer treatment, mitigating the impact of the pandemic.

Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the ABCSG Trial 5

2020 ◽  
Vol 26 (21) ◽  
pp. 5682-5688
Author(s):  
Zsuzsanna Bago-Horvath ◽  
Margaretha Rudas ◽  
Christian F. Singer ◽  
Richard Greil ◽  
Marija Balic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Predictive Value ◽  
Hormone Receptor ◽  
Molecular Subtypes ◽  
Premenopausal Women ◽  
Hormone Receptor Positive

Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer

Breast Cancer ◽  
2017 ◽  
Vol 24 (5) ◽  
pp. 714-719 ◽  
Author(s):  
Chinami Koga ◽  
Sayuri Akiyoshi ◽  
Mayumi Ishida ◽  
Yoshiaki Nakamura ◽  
Shinji Ohno ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Premenopausal Women ◽  
Hormone Receptor Positive

scholarly journals The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Eva Blondeaux ◽  
Claudia Massarotti ◽  
Valeria Fontana ◽  
Francesca Poggio ◽  
Luca Arecco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fertility Preservation ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Ovarian Function ◽  
Premenopausal Women ◽  
Primary Objective ◽  
Hormone Receptor Positive ◽  
Acceptance Rates ◽  
To Receive

BackgroundOffering ovarian function and/or fertility preservation strategies in premenopausal women with newly diagnosed breast cancer candidates to undergo chemotherapy is standard of care. However, few data are available on uptake and main reasons for refusing these options.MethodsThe PREFER study (NCT02895165) is an observational, prospective study enrolling premenopausal women with early breast cancer, aged between 18 and 45 years, candidates to receive (neo)adjuvant chemotherapy. Primary objective is to collect information on acceptance rates and reasons for refusal of the proposed strategies for ovarian function and/or fertility preservation available in Italy.ResultsAt the study coordinating center, 223 patients were recruited between November 2012 and December 2020. Median age was 38 years (range 24 – 45 years) with 159 patients (71.3%) diagnosed at ≤40 years. Temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) was accepted by 58 out of 64 (90.6%) patients aged 41-45 years and by 151 out of 159 (95.0%) of those aged ≤40 years. Among patients aged ≤40 years, 57 (35.8%) accepted to access the fertility unit to receive a complete oncofertility counseling and 29 (18.2%) accepted to undergo a cryopreservation technique. Main reasons for refusal were fear of delaying the initiation of antineoplastic treatments and contraindications to the procedure or lack of interest in future childbearing. Patients with hormone-receptor positive breast cancer had a tendency for a higher acceptance rates of ovarian function and/or fertility preservation strategies than those with hormone-receptor negative disease.ConclusionsMore than 90% of premenopausal women with early breast cancer, and particularly those with hormone receptor-positive disease, were concerned about the potential risk of chemotherapy-induced premature ovarian insufficiency and/or infertility and accepted GnRHa administration. Less than 1 out of 5 women aged ≤40 years accepted to undergo cryopreservation strategies.

Sign in / Sign up

Export Citation Format

Share Document